- Investing Ideas
- U.K. Pharmaceuticals & Biotech Healthy potentially undervalued
U.K. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
6
Companies which are potentially undervalued and in an acceptable financial position.
6 companies
GSK
Market Cap: UK£76.8b
Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK
UK£19.37
7D
-0.2%
1Y
40.0%
AstraZeneca
Market Cap: UK£186.7b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£118.50
7D
-6.8%
1Y
8.2%
Hikma Pharmaceuticals
Market Cap: UK£3.3b
Develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.
HIK
UK£16.99
7D
6.6%
1Y
-2.9%
Oxford Biomedica
Market Cap: UK£694.8m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£5.91
7D
4.6%
1Y
33.6%
hVIVO
Market Cap: UK£47.7m
Operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.
HVO
UK£0.069
7D
-11.0%
1Y
-32.7%
Diaceutics
Market Cap: UK£122.8m
A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.
DXRX
UK£1.50
7D
9.5%
1Y
8.7%